Abbvie Announces Positive Topline Results From Phase 2 Piccolo Trial Evaluating Mirvetuximab Soravtansine (Elahere) for High Folate Receptor-Alpha (FrΑ) Expressing Platinum-Sensitive Ovarian Cancer
艾伯維公司宣佈，從2期Piccolo試驗評估Mirvetuximab Soravtansine（Elahere）用於高葉酸受體-α（FrΑ）表達的鉑敏感性卵巢癌的陽性頂線結果。